The document discusses biomarkers and their use in disease diagnosis, drug development, and other applications. It provides an overview of the global biomarkers market, expected to reach $30.6 billion by 2020, with disease diagnosis as the major application. The market is analyzed by type, application, services, and geography. Key players in the biomarkers industry are also profiled.

1. Allied Market Research
Buy Now
Request Sample
Biomarkers Market (Diagnostic Applications in Risk
Assessment,
Molecular
Diagnostics,
Disease
Diagnosis, Drug Discovery & Development, Drug
Formulation, Forensic Applications and Others) - Global
Industry Analysis, Emerging Technologies, Competitive
Intelligence, Growth Trends, Size, Share, Opportunities
and Forecast, 2013 – 2020
Published
Date:
Single User License: US $ 4515
9-Dec-2013
Multi User License: US $ 7515
Corporate License: US $ 10515
151
Pages
Report
Report Description :
Biomarker technology is evidencing increased application from key
segments such as disease diagnosis, drug development and
formulation, diagnosis for exposure of certain harmful chemical and
prognostic treatments.

2. Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular
Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug
Formulation, Forensic Applications and Others) - Global Industry
Analysis,
Emerging
Technologies,
Competitive
Intelligence,
Growth
Trends, Size, Share, Opportunities and Forecast, 2013 - 2020

3. Description
Biomarker technology is evidencing increased application from key segments such as
disease diagnosis, drug development and formulation, diagnosis for exposure of
certain harmful chemical and prognostic treatments. Biomarkers are novel diagnostic
solutions and advancement in it its development and understanding of human genome
promotes its application in diagnosis of disease on molecular basis. Pharmaceutical
companies which are interested in introducing novel diagnostic solution are increasing
partnership and collaboration with private laboratories, educational institute and these
companies are also increasing their investments in research and development.
The global market for diagnostic biomarker expected to reach about $30.6 billion in
2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application
remains the key area of application that is expected to reach 6.1 $billion in 2020.
However application of diagnostic biomarkers in forensics and molecular diagnostics
is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR
of 17.6% from 2013 to 2020.

4. Global diagnostic Biomarker report segments the market in three categories; market
by technologies, market by services, and market by diseases. These markets are
expected to show elevated growth in future as biomarkers are providing diagnostic
service for complex disease. As it is non-invasive procedure it motivates the use of
biomarkers than conventional diagnostic applications. This report focuses on key
factors
impacting
the
diagnostic
biomarker
market
used
in
risk
assessment, molecular diagnostics, disease diagnosis, drug discovery and
development, drug formulation, forensic applications and others. Diagnostic
biomarker and its applications in emerging segments of omics, imaging
technologies, personalized medicine, and bioinformatics are all discussed in detail.

5. Key Deliverables
Biomarkers of disease are majorly covered by oncology, cardiovascular and Neurology
disease. Oncology biomarkers are covering more market share as compared to other
disease biomarkers. Other biomarker are facing some ethical and technical problem
such complex sample preparation process.
Biomarkers in service has open a new market for sample preparation for disease
diagnosis which enables clinicians to save time required for preparing sample to conduct
diagnostic test. Biomarkers are also resolving drug validation problem by analyzing
viability of drug discovered by pharmaceutical research.
The key players in this market that are also profiled in the report include Roche
Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories
Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), BioRad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.), Epistem Ltd.(U.K.), G.E.
Healthcare Inc.(U.K).

6. Key Benefits of Report
Assessment and ranking the factors that favour the market growth and those factors which act as
a hindrance for the growth of the market
The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011
and 2012
The report identifies and analyses top investment pockets and top winning strategies for
diagnostic biomarker market
The report analyses the various strategies adopted by some of the key companies in the market
The report tracks and analyses key innovations and patents for biomarkers in the last five years

7. Table of content
1. Introduction
2. Executive Summary
3. Market Overview
4. Global Diagnostic Biomarkers Market by Types
5. Global Diagnostic Biomarkers Market by Applications
6. Global Diagnostic Biomarkers Market by Services
7. Global Diagnostic Biomarkers Market by Geography
8. Competitive Landscape
9. Company Profile

8. Introduction
Scope of the report
of the Market Report
Report Description

9. Chapter 1 Introduction
1.1 Scope and Coverage
1.2 Report Description
Chapter 2 Executive Summary
2.1 Biomarker Diagnosis Vs. Conventional Diagnosis
2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug
Development?
Chapter 3 Market Overview
3.1 Key Application of Diagnostic Biomarkers in Top Technologies
3.1.1 Omics Technology
3.1.1.1 Applications of Omics Technology
3.1.1.1.1 Lung Disease Identification
3.1.1.1.2 Quantifying Abnormalities
3.1.1.1.3 Genetic Trait Diagnosis
3.1.1.1.4 Analyzing Drug Efficiency
3.1.1.1.5 Functional Food Development
3.1.1.1.6 Pharmacogenomics
3.1.1.1.7 Drivers

10. 3.1.1.1.8 Restraints
3.1.1.1.8.1 Lengthy Process
3.1.1.1.8.2 Ethical Problems
3.1.1.1.8.3 Sample Collection
3.1.1.1.8.4 Gene Expression
3.1.1.1.8.5 Inefficiency in Pre-Disease Identification
3.1.2 Imaging Technology
3.1.2.1 Application of Diagnostic Imaging Technology
3.1.2.2 Drivers
3.1.2.2.1 Faster Test Result
3.1.2.2.2 Improved Nursing Services
3.1.2.2.3 Noninvasive Technique
3.1.2.3 Restraints
3.1.2.3.1 Radiation Effect
3.1.2.3.2 Complex Process
3.1.2.3.3 Genetic Variation
3.1.2.4 Trends

11. 3.1.3 Bioinformatics
3.1.3.1 Applications of Bioinformatics
3.1.3.2 Drivers
3.1.3.2.1 Open Source of Information
3.1.3.2.2 Relevant Information
3.1.3.2.3 Forecasting of Information
3.1.3.3 Restraints
3.1.3.3.1 Difficulty in Practical Application
3.1.3.3.2 Over-Fitting
3.1.3.3.3 Complex Operation Process
3.1.3.3.4 Security Issue
3.1.3.3.5 Costly Management
3.1.3.3.6 Virtual Storage
3.1.4 Personalized Medicines
3.1.4.1 Drivers
3.1.4.1.1 Unique Solution
3.1.4.1.2 Minimal Invasive
3.1.4.1.3 Reduction in Failure
3.1.4.1.4 Effective Prescription

12. 3.2
3.3
3.4
3.5
3.6
3.7
3.1.4.2 Restraints
3.1.4.2.1 Need Specialized Setup for Treatment
3.1.4.2.2 Liability Issue
3.1.4.2.3 Ethical Question
3.1.5 Others (Nutritional Technology)
Importance of Non-Invasive Diagnostics
Key Advantages of Dm
Regulatory Scenario
Reimbursement Issues
Key Patents and Analysis
Top Ten Factors Impacting DBM Market
3.7.1 Non-Invasive Technique
3.7.2 Drug Discovery and Development
3.7.3 Cost Effective Tool for Diagnosis
3.7.4 Multi-Marker Application
3.7.5 Accuracy and Reliability
3.7.6 Ethical Issues
3.7.7 Gene Level Diagnosis

13. 3.7.8 Complex Processes
3.7.9 Government Regulations
3.7.10 Reimbursement Issues
3.8
Top Investment Pockets
3.9
Market Intelligence
3.9.1 Top Three Winning Strategies
3.9.1.1 Product Launch
3.9.1.2 Collaboration and Agreement
3.9.1.3 Merger and Acquisition
3.10 Market Dynamics
3.10.1 Drivers
3.10.1.1 Cost Effective
3.10.1.2 Non-Invasive
3.10.1.3 Accuracy in Result
3.10.1.4 Assistant in Clinical Trials
3.10.1.5 Multi-Marker Application
3.10.1.6 Gene Level Diagnosis
3.10.2 Restrains
3.10.2.1 Government Regulation
3.10.2.2 Ethical Problems

14. 3.10.2.3 Conformation in Result
3.10.2.4 Complex Process
3.10.3 Opportunity
3.10.3.1 Local Market
3.10.3.2 Personalized Medicine
3.10.3.3 Tissue Specific Treatment
Chapter 4 Global Diagnostic Biomarker Market by Types
4.1
Biomarker of Exposure
4.2
Biomarkers of Disease
Chapter 5 Global Diagnostic Biomarker Market by Applications
5.1
Risk Assessment
5.1.1 Applications
5.1.1.1 Oncology Treatment
5.1.1.2 Cardiovascular Treatment
5.1.2 Drivers
5.1.2.1 Forecasting of Abnormal Conditions
5.1.2.2 Cost Effective

15. 5.1.3 Restraints
5.1.3.1 Government Regulations
5.1.3.2 Ethical Issues
5.2
Development of Molecular Diagnostic
5.2.1 Application
5.2.1.1 Prenatal Diagnostics
5.2.1.2 Human Clinical Molecular Diagnostic Testing
5.2.1.3 Veterinary Molecular Diagnostic Testing
5.2.1.4 Identity Testing
5.2.1.5 Histocompatibility Testing
5.2.2 Drivers
5.2.2.1 Uniformity in Test Result
5.2.2.2 Cost Effective
5.2.2.3 Fast Result
5.2.2.4 More Profitable
5.2.2.5 Automation
5.2.3 Restraints
5.2.3.1 Not Applicable for Twins Genomes
5.2.3.2 Government Regulations
5.2.3.3 Ethical Issues

16. 5.3
Disease Diagnosis
5.3.1 Oncology
5.3.1.1 Drivers
5.3.1.2 Restraints
5.3.1.2.1 Complex Process
5.3.1.2.2 Conformation in Result
5.3.1.2.3 Used for Early Diagnosis Only
5.3.2 Cardiology
5.3.2.1 Application
5.3.2.2 Drivers
5.3.2.2.1 Cost Effective
5.3.2.2.2 Tissue Specific
5.3.2.2.3 Accurate Result
5.3.2.3 Restraints
5.3.2.3.1 Loss of Specificity
5.3.2.3.2 Low Specificity
5.3.2.3.3 Low Sensitivity
5.3.3 Neurology
5.3.3.1 Application
5.3.3.2 Drivers

17. 5.3.3.2.1 Relevant Information
5.3.3.2.2 Efficient Diagnosis
5.3.3.2.3 Assistant in Clinical Trials
5.3.3.3 Restraints
5.3.3.3.1 Complex Process
5.3.3.3.2 Chromosomal Variation
5.3.3.3.3 Hurdles in Tracking
5.3.3.4 Alzheimer’s
5.3.3.5 Multiple Sclerosis
5.3.3.6 Parkinson's Disease
5.3.3.7 Others (Renal Diseases, Urinal Disease)
5.4
Drug Discovery and Development
5.4.1 Application
5.4.2 Drivers
5.4.2.1 Increased Efficiency
5.4.2.2 High Quality Support
5.4.2.3 Cost Effective
5.4.2.4 Collaboration for Novel Development
5.4.3 Restraints
5.4.3.1 Drug Metabolism

18. 5.4.3.2 Stability of Biomarkers
5.4.3.3 Complex Process
5.5
Drug Formulation
5.5.1 Application
5.5.2 Drivers
5.5.3 Restraint
5.6
Forensic Application
5.7
Others (Dna Fingerprinting and Others)
5.7.1 Blood Alcohol Concentration Biomarker
5.7.2 Dna Fingerprinting
Chapter 6 Global Diagnostic Biomarker Market by Services
6.1
Sample Preparation
6.1.1 Application
6.1.1.1 Biological Mass Spectrometry
6.1.2 Drivers
6.1.2.1 Cost Effective
6.1.2.2 Sample Rigidity
6.1.2.3 Efficient Forensic Studies
6.1.3 Restraints

19. 6.1.3.1 Complex Structure
6.1.3.2 Lack of Effectiveness
6.1.3.3 Extensive Fractionation
6.1.3.4 Loss of Biological Compounds
6.2
Assay Development
6.2.1 Application
6.2.1.1 Clinical Trials
6.2.1.2 Drug Development and Validation
6.2.1.3 Others
6.2.2 Drivers
6.2.2.1 Accuracy
6.2.2.2 Cost Effective
6.2.2.3 Timely Result
6.2.3 Restraints
6.2.3.1 Complexity in Technique
6.2.3.2 Tissue Specific
6.3
Biomarker Validation and Testing
6.3.1 Drivers
6.3.1.1 Reduce Failure Rate
6.3.2 Restraints

20. 6.3.2.1 Clinical Errors
6.3.2.2 Time Consuming
6.4
Other Services
Chapter 7
7.1
7.2
7.3
7.4
Global Diagnostic Biomarker Market by Geography
North America
Europe
Asia-Pacific
Row (Rest of World)
Chapter 8 Competitive Landscape
8.1
Product Launch
8.1.1 Recent Development
8.2
Collaboration and Partnership
8.2.1 Recent Development
8.3
Clearance and Approval
8.3.1 Recent Development
8.4
Mergers and Acquisition
8.4.1 Recent Development

21. Chapter 9 Company Profile
9.1
Abbott Laboratories, Inc.
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Business Performance
9.1.4 Strategic Moves and Developments
9.1.4.1 Principal Strategies
9.1.4.2 Secondary Strategies
9.1.5 Swot Analysis & Strategic Conclusions
9.2
Agilent Technologies Inc.
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Business Performance
9.2.4 Strategic Moves and Developments
9.2.4.1 Primary Strategies
9.2.4.2 Secondary Strategies
9.2.5 Swot Analysis & Strategic Conclusions
9.3
Aushon Biosystem
9.3.1 Company Profile
9.3.2 Company Snapshot
9.3.3 Strategic Moves and Developments
9.3.3.1 Primary Strategies

22. 9.3.3.2 Secondary Strategies
9.3.4 Swot Analysis & Strategic Conclusions
9.4
Bio-Rad Laboratories
9.4.1 Company Profile
9.4.2 Company Snapshot
9.4.3 Business Performance
9.4.4 Strategic Moves and Developments
9.4.4.1 Primary Strategies
9.4.4.2 Secondary Strategies
9.4.5 Swot Analysis & Strategic Conclusions
9.5
Eisai Co. Ltd.
9.5.1 Company Profile
9.5.2 Company Snapshot
9.5.3 Business Performance
9.5.4 Strategic Moves and Developments
9.5.4.1 Primary Strategies
9.5.4.2 Secondary Strategies
9.5.5 Swot Analysis & Strategic Conclusions

23. 9.6
Epistem Ltd.
9.6.1 Company Profile
9.6.2 Company Snapshot
9.6.3 Business Performance
9.6.4 Strategic Moves and Developments
9.6.4.1 Primary Strategies
9.6.4.2 Secondary Strategies
9.6.5 Swot Analysis & Strategic Conclusions
9.7
Ge Healthcare
9.7.1 Company Profile
9.7.2 Company Snapshot
9.7.3 Business Performance
9.7.4 Strategic Moves and Developments
9.7.4.1 Principle Strategies
9.7.4.2 Secondary Strategies
9.7.5 Swot Analysis & Strategic Conclusions
9.8
Roche Diagnostics Limited
9.8.1 Company Profile
9.8.2 Company Snapshot

24. 9.7.3 Business Performance
9.7.4 Strategic Moves and Developments
9.7.4.1 Principle Strategies
9.7.4.2 Secondary Strategies
9.7.5 Swot Analysis & Strategic Conclusions
9.8
Roche Diagnostics Limited
9.8.1 Company Profile
9.8.2 Company Snapshot
9.8.3 Business Performance
9.8.4 Strategic Moves and Developments
9.8.4.1 Principal Strategies
9.8.4.2 Secondary Strategies
9.8.5 Swot Analysis & Strategic Conclusions
9.9
Siemens AG
9.9.1 Company Profile
9.9.2 Company Snapshot
9.9.3 Business Performance

25. 9.9.4 Strategic Moves and Developments
9.9.4.1 Primary Strategies
9.9.4.2 Secondary Strategies
9.9.5 Swot Analysis & Strategic Conclusions
9.10 Thermo Fisher Scientific Inc.
9.10.1 Company Profile
9.10.2 Company Snapshot
9.10.3 Business Performance
9.10.4 Strategic Moves and Developments
9.10.4.1 Primary Strategies
9.10.4.2 Secondary Strategies
9.10.5 Swot Analysis & Strategic Conclusions

26. The geographic analysis is based on North America., Europe, Asia-Pacific and Rest of
the World.
North America
Geographic
Analysis
Rest Of The World (ROW)
Europe
Asia-Pacific (APAC)

27. Topics Covered in Company Profiles
Company Overview
Business Performance
Key Financials
Strategies
SWOT Analysis

28. Top Market Players
 Abbott Laboratories Inc.
 Agilent Technologies Inc.
 Aushon Biosystem
 Bio-Red laboratories
 Eisai Co. Ltd
 Epistem Ltd
 Ge HealthCare
 Roche Diagnostics Limited
 Siemens AG
 Thermo Fisher Scientific Inc.

29. Visit Website
Connect with us
Linked In
Face Book
Twitter
Google +